Clinical Trial: Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06822790) titled 'Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia' on Feb. 07.

Brief Summary: This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-3001 (NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (NCT06347133). All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remain on the specified low-fat diet ...